pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-628 |
Genomic Coordinates | chr15: 55372940 - 55373034 |
Synonyms | MIRN628, hsa-mir-628, MIR628 |
Description | Homo sapiens miR-628 stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-628-3p | ||||||||||||||||||||||||||||
Sequence | 61| UCUAGUAAGAGUGGCAGUCGA |81 | ||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||
Experiments | Microarray | ||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
DRVs in miRNA |
|
||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | LRAT | ||||||||||||||||||||
Synonyms | LCA14 | ||||||||||||||||||||
Description | lecithin retinol acyltransferase | ||||||||||||||||||||
Transcript | NM_004744 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on LRAT | |||||||||||||||||||||
3'UTR of LRAT (miRNA target sites are highlighted) |
>LRAT|NM_004744|3'UTR 1 CTTCATACCCCCATGTCAGTGTGTGTATTCTGTATGTAAATATGTTTATATTTATAGAGCATCAATCAATATAAGCATTA 81 TTGAGAAAAATGTGACCCGTAACACTGTGTTCTGGATAAAAATGTGATTAGGAATCACGCAAAGTGCTTACTGTGTAAGC 161 CCAAGAACAAAGGCTTTCTGAATCTTCTCAGGCAGTTCAGATTTAAAGCACCATCCAAACCTTGGAAATACGACAGGGTG 241 TGGTAGAATTCAGCAATATGAGAAAACCAGCCCCTAAAATGATAGCCACAAGAGATTAATTGTGTTTTTTTTTCTCCTGT 321 AATCCTTGTACTGTTCGGCTGAATTTGAAGATTGGAAGACTTATATTGAGACCAGTAACTTTACTGTAAATTTACTTTGT 401 TTCATTGAAAAAACAAATTGATAAACATATTAAACTGGAAGAATTTTCTTTATTCAAATGAAAACATGTTTGATGACTGG 481 TCAAAAAATAAGCTCATAATCTATTTTTTTCATGTAGTATATAAGTCAAGAATGTTTTATTGTCATTATGTGAAACCAAT 561 ATTGGCAAATAGTACTTTAATGATGAAGTAAATGACCAGAAATTATAGAAATCTGTGTTTTCCTGTAAAAATAGCACTAT 641 AGTATCACTTGAACAATTTGATTTGGCTTTACTTACTAGGAAGCCTGGAATTCATTATTTTTTTCCTTTTATGTGCCACT 721 GTGGCTACTTTAAATCACTCTGAGAGGTAAATGGATATAGGATTGAAGTTATGTGGGTATTTGGCATGTGTGTGTGAAAT 801 AAATATGTAGATAGTCACATATACACAGACTGAGAGATAAATTGTTCTTGATTGCTTTATTATCATCATACTAGTGTGTT 881 CATTATAGAGTATCTGTAGAGGTGAATGTAAAAGTAAGTCCAATCTATTTTCTTATGTCATTGAATTTGTAGTGTTAACT 961 TGCATATATGTTATTGGATGGGTTGTCTTTTAAAGCATTTACTAATGTACTCTGAAATTTTTAAAAGCCTTCAGATTTGT 1041 TTTCTAGTCACTTTTTTCCATATCATTTCTAATTATAGTTTATATCCTTAAAAGAAGGATGCCACAGTAGTATGTAAAAC 1121 CCAAACAAGTAGAACCCAAGCAAATAAAATTATTTAAAATAATTTTAAAGTGGCTTAGTACTGCCAGTCATGTAAATTGA 1201 TTCTGCTGAGGGTCTTATAAGAATTGAGATATAACAATGGTAAAACAAGCATTCAAGCACTTTTACAAAATTACCAAATT 1281 CTTAAAATGAAGCCACAGCTAGACTTGCATTTCAGGTATTAAAATTGCTTTCTTAACTGTCAAGAATCACAAAATAACAA 1361 ATCATATTATGAGTGAATATGGGGAGGGCGGGGCCAATCAGTCAATGATAATCTGAACAAATTTTAAGAGCAGATTTTAG 1441 ATTAATAATGTTTTATCACCACTAATTTGCCCACAACAAACTCAGTATTTAATTTTTCAAATTAAATATTAAATTATTTA 1521 AGTATTTTAAATAATTAAAACATTAAATGGCAACACCATAGAATATAGGTGTTCTCTGGACCTATTCTAACCACTTAAAA 1601 TTATCTTAAGTATGCATACATAAAAGCAACCACTATGAGAACTACCGTGTTAGTGGTTTTTCACTTACTGTATATTACCC 1681 TTGTAGGAATAGTTTAAGGAAATTCATTTCTTAAAAATATAGTGTCCTCAAATAATTAATTTTTTTGCAAACTTTAGTTA 1761 TTACAGGCAGCAAAAACCACTGTCTGAAACTAAATCTGTGTTCAAAGATGAAGACCCCTCATTAAAAGCCAAGGACGTTC 1841 TTAAGATTGGAACTGACATAATTAGTCTTGACTTACTTCATTAAAGCAAGATTCAATTCCTTGTTCATTTGAGTGTTCAT 1921 TATATGCCAGGCATTGACCAGTTGCAATTTTATGGTCCAGAATTAATATTATTATTCGTAAACTAGCTATAATAGAGTAT 2001 ATACAGTGCTGTGGGAATACAGGGGAAGAAGCAATTAAATCTGCTAGAAGGGTAAGAGAAATCTGTATGCAGGAGGCAAT 2081 GCTAGCATTAAGCCAAGAAATAGTGTGAGGTGATCTTATCACACTGATGTGTTCAACTGTTTATGGGAAAAGGAAACTAG 2161 GATGGTTTTATTTGTGAAATGTTCTACAACGCTAGAACTGTTGAACTTCTTGGGAGAAAAGGAGAATCTTTGTTTTGTTG 2241 TGCTGAGTTTGATTAGTTGCTTAACCAAGTAGAAAGAAAAGCACATCTTCCTGATCACAGTTATAAAAGAAACCCTGAGG 2321 CCGGGCGCGGTGGCTCAAGCCTGTAACCCCAGCACTTTGGGAGGCCAAGGAGGGAGGATCACAAGGTCAGGAGATCGAGA 2401 CCATCCTGGCTAACACGGTGAAACCCCATCTCTACTAAAAATACAAAATTAGCTGGGCGTGGTGGCCGGCGCCTGTAGTC 2481 CCAGCTACTCATGAGGTTGAGGCAGGAGAATGGCGTGAACCGAGGAGGCGGAGCTTGCAGTGAGTGGAAATTGCGCCACT 2561 GCACTCCAGCCTGGGCAACAAAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAAGAAACC 2641 CTGAGCCATTAATGTGTCTCGTAACTTGAGGAAGTTCATGAATTCTCTGGGCTTCATCCATTAAGATTCATCCTTATGCT 2721 CCTGCAAGTTTCTTATATTTATGTATTTCTATTCTGATTTCTGAAATGATAACCTAGTAGTGTCTGATGAAGTTTTTTCA 2801 TGCTTATTTTATTCTTTGTCACAGATGAAAGAAGAATAGGACTAATTGGGGCTAAGATGAATTAATGTAAGTGTCAGATA 2881 CTAGGCAGGTGTTAGGGATGAAATGATGAATGAGGCATGGACCTGTTCCTCAGAGTTTATGGCCCAGTAGACATAATTGT 2961 ATTAGGACTTTCTGCAGTTGACATTTGCATAAAGCTGACTGACTGAAGGAACAGAAAGTGAGACAGACAGATATGACCAA 3041 ATTTATACAAACCATGTACCAACACTTGAAAGATGGGTGGATATTTTCCAGGAAACAGATTTTGGGCAGGACATTCCATG 3121 CACTGGAAATAGCATGAACAAATGCATGAAAATTGCCTACAACATGCCTGGCACATAGCTGTGAGGTACCCTATGAGTTG 3201 TTGACTTGAAAACATGGAACTGCACAGGGCATTCAGGCAAGTGCAAGTGGTTCAGGGGCCAGCGCAGAGCAGAGTGCTGA 3281 GTAAAGATGTCAGAAAAGGAAAGCAATGGTCTGGTACAAGTCTTGTATAGAACAAGAAGTTTAGACTTTTGAACAGGCAA 3361 TCGAGATTTGGGGTTCAGAAAGATAAATCCCAAAAGTATGGAGAACAAAGGAACTCATTTTAAAGGACTAGCTAAGATGC 3441 TCAATCTCTAAAAAAAAAAGGATCTGTATTCGTGAGAGTAGAGAGAAAGGTTGTTTAGGAAGAGTCAACAGACTTTAGCA 3521 AAATCCTTTTATTTGATTCATGCATAACTCCTGATGGAGTGTCAAGGAAGACTCATTCACTTTTCTTTCCTGCCAGAAAG 3601 TTGGTTCTTGCAAAATAGATTAACTTGATGACTATGTGTATATTGGATACTCCTAATTTTAGCTCTGTTAGATATGTTTC 3681 TTTCTAAGGACAAGCAACTATGTATAGACTTGTTGTTTGAATTTTTTTTCAGTATATATATGTTTCTTGTTTTTCTATTT 3761 TTCTACTTCATACTGTTAATGTCAAATATCAAAAATGTTTTCCAGCAATATCAAGTTATGGCAATGGCAAAAGTCCTTGT 3841 TGTAGATGAGAAGCATATAAGAAATGGTTGCCAATCTTTGTTTTGTATGATCTATTTAGAGTTTTAACCAACCTAGATCT 3921 GTCAGCTAAGCTAATTTTATATTTGGTATACATGCATGTCAAATAAAGTTAATTTTACATACT Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | BC-3 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796040. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
CLIP-seq Support 1 for dataset GSM796040 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-3 / 4-Thiouridine |
Location of target site | ENST00000336356.3 | 3UTR | UUGGCUUUACUUACU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
27 hsa-miR-628-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT039584 | CDC14A | cell division cycle 14A | 1 | 1 | ||||||||
MIRT039585 | AGO1 | argonaute 1, RISC catalytic component | 2 | 3 | ||||||||
MIRT039586 | TGFBRAP1 | transforming growth factor beta receptor associated protein 1 | 1 | 1 | ||||||||
MIRT039587 | LRP6 | LDL receptor related protein 6 | 1 | 1 | ||||||||
MIRT071876 | BTF3L4 | basic transcription factor 3 like 4 | 2 | 2 | ||||||||
MIRT097443 | JMY | junction mediating and regulatory protein, p53 cofactor | 2 | 4 | ||||||||
MIRT100100 | ABT1 | activator of basal transcription 1 | 2 | 8 | ||||||||
MIRT147692 | CBX4 | chromobox 4 | 2 | 2 | ||||||||
MIRT408248 | PURA | purine rich element binding protein A | 2 | 2 | ||||||||
MIRT442047 | LRAT | lecithin retinol acyltransferase | 2 | 2 | ||||||||
MIRT444412 | RAB3IP | RAB3A interacting protein | 2 | 2 | ||||||||
MIRT452599 | REPIN1 | replication initiator 1 | 2 | 2 | ||||||||
MIRT469515 | RBFOX2 | RNA binding protein, fox-1 homolog 2 | 2 | 8 | ||||||||
MIRT498192 | AKR1B10 | aldo-keto reductase family 1 member B10 | 2 | 2 | ||||||||
MIRT500151 | CREBBP | CREB binding protein | 2 | 2 | ||||||||
MIRT507319 | FAM60A | SIN3-HDAC complex associated factor | 2 | 6 | ||||||||
MIRT508343 | ZNF273 | zinc finger protein 273 | 2 | 6 | ||||||||
MIRT520480 | TRIM13 | tripartite motif containing 13 | 2 | 2 | ||||||||
MIRT522461 | MMP16 | matrix metallopeptidase 16 | 2 | 4 | ||||||||
MIRT547116 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | 2 | 2 | ||||||||
MIRT548675 | CRNKL1 | crooked neck pre-mRNA splicing factor 1 | 2 | 2 | ||||||||
MIRT553756 | TARBP2 | TARBP2, RISC loading complex RNA binding subunit | 2 | 4 | ||||||||
MIRT559437 | ARSJ | arylsulfatase family member J | 2 | 2 | ||||||||
MIRT610490 | GPC4 | glypican 4 | 2 | 2 | ||||||||
MIRT644682 | TMCO1 | transmembrane and coiled-coil domains 1 | 2 | 2 | ||||||||
MIRT658214 | FBXO21 | F-box protein 21 | 2 | 2 | ||||||||
MIRT756083 | TP53 | tumor protein p53 | 4 | 1 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|